Liu Jing, Yu Yang, Sun Jing-yan, He Shan-shan, Wang Xin, Yin Jian, Cao Xu-chen
Department of Breast Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.
Breast Cancer Res Treat. 2015 Jan;149(1):133-40. doi: 10.1007/s10549-014-3224-z. Epub 2014 Dec 5.
Primary squamous cell carcinoma of the breast (PSCCB) is a rare type of breast carcinoma, the clinical behavior of which has not been accurately characterized. The aim of this study was to evaluate its prevalence, characteristics, prognosis, and effective treatment modalities in patients attending our institution. The records of the Cancer Institute and Hospital of Tianjin Medical University from 1985 to 2013 were searched and 29 patients with PSCCB (0.086 % of all patients with breast cancer) identified. Their clinicopathological features, treatment methods used, and outcomes were analyzed. The median tumor size was 4.50 cm. Axillary lymph nodes metastases were present in 41.4 % of patients. The median overall survival was 39 months (range 7-144 months), with 34.5 % surviving at 5 years. The median relapse-free survival was 32 months (range 4-144 months), with 27.6 % relapse-free surviving at 5 years. According to univariate analysis, the time interval between onset of the first symptom and first presentation to a health professional (TI) (P = 0.017), use of adjuvant chemotherapy (P = 0.044), and T stage (P = 0.048, T1 vs. T2, T3, T4) were significant prognostic factors for overall survival. PSCCB is an extremely aggressive disease associated with large tumor size, rapid progression, frequent relapse, and a high death rate. Imaging findings are nonspecific and easily misinterpreted as benign. Cisplatin-based chemotherapy may be effective. Early diagnosis and treatment of this rare entity are critical to patient prognosis.
乳腺原发性鳞状细胞癌(PSCCB)是一种罕见的乳腺癌类型,其临床行为尚未得到准确描述。本研究的目的是评估在我院就诊患者中其患病率、特征、预后及有效治疗方式。检索了天津医科大学肿瘤研究所和医院1985年至2013年的记录,共识别出29例PSCCB患者(占所有乳腺癌患者的0.086%)。分析了他们的临床病理特征、所采用的治疗方法及治疗结果。肿瘤中位大小为4.50 cm。41.4%的患者存在腋窝淋巴结转移。总生存期中位时间为39个月(范围7 - 144个月),5年生存率为34.5%。无复发生存期中位时间为32个月(范围4 - 144个月),5年无复发生存率为27.6%。单因素分析显示,首发症状出现至首次就诊于医疗专业人员的时间间隔(TI)(P = 0.017)、辅助化疗的使用(P = 0.044)以及T分期(P = 0.048,T1与T2、T3、T4相比)是总生存的重要预后因素。PSCCB是一种极具侵袭性的疾病,与肿瘤体积大、进展迅速、频繁复发及高死亡率相关。影像学表现无特异性,易被误诊为良性。以顺铂为基础的化疗可能有效。对这种罕见疾病进行早期诊断和治疗对患者预后至关重要。